Advertisement
Drug Pipeline
Subscribe to Drug Pipeline
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

'Unsung' Cells Double the Benefits of a New Osteoporosis Drug

October 8, 2014 10:48 am | News | Comments

Experiments in mice with a bone disorder similar to that in women after menopause show that a scientifically overlooked group of cells are likely crucial to the process of bone loss caused by the disorder, according to Johns Hopkins researchers. Read more...

3 Win Nobel for Super-Zoom Microscopes

October 8, 2014 10:16 am | by Karl Ritter and Malin Rising | News | Comments

Two Americans and a German scientist won the Nobel Prize in chemistry for finding ways to make microscopes more powerful than previously thought possible, allowing scientists to see how diseases develop inside the tiniest cells. Read more...

A Universal Ebola Drug Target

October 8, 2014 10:05 am | News | Comments

University of Utah biochemists have reported a new drug discovery tool against the Ebola virus. According to a study published in the online edition of Protein Science, they have produced a molecule, known as a peptide mimic, that displays a functionally critical region of the virus that is universally conserved in all known species of Ebola. Read more...

Advertisement

FDA Grants Fast Track Designation to NurOwn for the Treatment of ALS

October 7, 2014 2:45 pm | News | Comments

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the United States Food and Drug Administration (FDA) has designated NurOwn as a Fast Track product for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). Read more...

A New Pathway Discovered Regulating Autoimmune Diseases

October 7, 2014 2:32 pm | News | Comments

The main function of the immune system is to protect against diseases and infections. For unknown reasons our immune system attacks healthy cells, tissues and organs in a process called autoimmunity, which can result in diseases such as multiple sclerosis, type 1 diabetes, lupus or rheumatoid arthritis. There are currently no existing cures for these diseases. Read more...

Vivolux Cancer Drug Receives FDA Clearance for Clinical Study

October 7, 2014 2:21 pm | News | Comments

Vivolux, a pharmaceutical company specialized in cancer treatment, announced that the FDA has granted clearance to proceed with VLX1570 to clinical phase 1/2 for treatment against relapsed and/or refractory multiple myeloma. Read more...        

Experimental Drug Provided to Dallas Ebola Patient

October 7, 2014 10:57 am | by Matthew Perrone, AP Health Writer | News | Comments

A North Carolina drugmaker is providing its experimental antiviral drug to a Dallas patient being treated for Ebola, an emergency step authorized by the Food and Drug Administration. Read more...                                    

Acacia Pharma Gets Positive Results for PONV Treatment

October 7, 2014 10:36 am | News | Comments

 Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). Read more...                                   

Advertisement

Researchers Develop Personalized Ovarian Cancer Vaccines

October 7, 2014 10:02 am | News | Comments

Researchers at the University of Connecticut have found a new way to identify protein mutations in cancer cells. The novel method is being used to develop personalized vaccines to treat patients with ovarian cancer. Read more...         

Mylan Launches Generic HIV-1 Treatment

October 6, 2014 3:21 pm | News | Comments

Mylan Inc. announced the U.S. launch of its Lamivudine and Zidovudine Tablets USP, 150 mg/300 mg, which is the generic version of Viiv's Combivir. Read more...                                

Teva Announces Results of Review of Core Specialty Therapeutic Areas

October 6, 2014 10:32 am | News | Comments

Teva Pharmaceutical announced results of its strategic review of core therapeutic areas for the company. The review included an extensive evaluation of Teva’s current and future capabilities to address unmet patient needs, the competitive landscape, barriers to entry and profitability with the purpose of creating a winning strategy to achieve global leadership in each of the company's core therapeutic areas. Read more...

Alcobra Gets Positive Results for Adult ADHD Drug

October 6, 2014 10:22 am | News | Comments

Alcobra Ltd., an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, announced topline results from a Phase 3 study of Metadoxine Extended Release (MDX) in adults with ADHD. Read more...

‘Programmable’ Antibiotic Harnesses Enzyme to Attack Drug-Resistant Microbes

October 6, 2014 10:12 am | News | Comments

The multitude of microbes scientists have found populating the human body have good, bad and mostly mysterious implications for our health. But when something goes wrong, we defend ourselves with the undiscriminating brute force of traditional antibiotics, which wipe out everything at once, regardless of the consequences. Read more...

Advertisement

CEL-SCI Enrolls 16 New Patients in Phase 3 Cancer Trial

October 3, 2014 3:33 pm | News | Comments

CEL-SCI Corp. announced that during the month of September the company enrolled 16 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase 3 trial. Read more...             

New Technology Isolates Tumor Cells from Blood to Optimize Cancer Therapy

October 3, 2014 3:29 pm | News | Comments

A team of bioengineers, molecular biologists, and clinicians used a novel rare cell-sorter to isolate breast cancer cells from the blood of patients, with the aim of identifying the most effective drugs to treat each individual tumor. Read more...

Fasting Blood Biomarker a-HB Predicts Diabetes Risk

October 3, 2014 3:11 pm | News | Comments

Could a single serum biomarker predict risk for diabetes as accurately as a more complex, hours-long diagnostic procedure? According to researchers at Health Diagnostic Laboratory Inc. and the University of Utah, the answer is "yes." Read more...

Neurocrine Initiates Clinical Trial for Tourette Syndrome Therapy

October 3, 2014 2:58 pm | News | Comments

Neurocrine Biosciences, Inc. announced that it has initiated a clinical trial of NBI-98854, a proprietary small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in both children and adolescents with Tourette syndrome. Read more...      

Halozyme Gets Orphan Drug Designation for Pancreatic Cancer Drug

October 3, 2014 2:49 pm | News | Comments

Halozyme Therapeutics, Inc. announced that the FDA has granted Orphan Drug designation for PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer. Read more...                             

Record Number of Clinical Trials for Multiple Myeloma this Year

October 3, 2014 2:11 pm | News | Comments

The Multiple Myeloma Research Consortium (MMRC) announced that it has opened six new clinical trials in 2014, and is on track to open more multiple myeloma clinical trials during 2014 than any other year since the Consortium was founded in 2004. Read more...

Potential Therapy Spotted for Sudan Strain of Ebola

October 3, 2014 11:04 am | by Stephanie Guzowski, Editor | Articles | Comments

As the deadly Ebola outbreak in West Africa continues to grip headlines around the world, researchers move steadily forward with drug development. But as essential as it is to contain the current Ebola outbreak, researchers are looking at the bigger picture— and highlighting the need for therapy development to extend beyond the wake of the current epidemic. Read more...

Intarcia Announces Positive Results for Type 2 Diabetes Therapy

October 2, 2014 3:33 pm | News | Comments

Intarcia Therapeutics announced successful top-line results from two of its four phase 3 clinical trials for ITCA 650 . The first trial, FREEDOM-1, was a placebo-controlled, double-blind phase 3 clinical trial that tested the efficacy and safety of ITCA 650 in patients with type 2 diabetes against placebo. Read more...

Ariad's Lung Cancer Drug Receives FDA Breakthrough Therapy Designation

October 2, 2014 3:21 pm | News | Comments

Ariad Pharmaceuticals, Inc. announced that its investigational cancer medicine, AP26113, has received Breakthrough Therapy designation by the FDA for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who are resistant to crizotinib. Read more...

NKT Therapeutics’ Sickle Cell Disease Drug Receives FDA Fast Track

October 2, 2014 2:42 pm | News | Comments

NKT Therapeutics announced that FDA has granted Fast Track designation to NKTT120, the company’s lead therapeutic being developed for the treatment of sickle cell disease. Read more...

Experimental Ebola Vaccine Processed in Maryland

October 2, 2014 2:22 pm | News | Comments

The National Institute of Allergy and Infectious Diseases said an experimental Ebola vaccine is being processed at a facility in Frederick. The Frederick News-Post reported that the vaccine is a joint project between the federal agency and GlaxoSmithKline. Read more...

Amgen Announces Positive Data for Cholesterol-Lowering Medication

October 2, 2014 2:12 pm | News | Comments

Amgen announced The Lancet published data from two Phase 3 studies, RUTHERFORD-2 and TESLA, that showed treatment with evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication, resulted in a statistically significant reduction in LDL-C compared to placebo in patients with different types of familial hypercholesterolemia (FH). Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading